Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Eli Lilly and Novo Nordisk have both assuaged investor concerns over near-term growth. Now the focus shifts back to their ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...